Researchers report experimental drug may prolong survival in ALS patients
Trial drug combination shows potential to prolong survival of ALS patients by more than six months.
Trial drug combination shows potential to prolong survival of ALS patients by more than six months.
UF was the No. 2 enroller of patients for multisite ALS trial.
Dr. James Wymer among national team of researchers to identify novel pathway for potential treatment of the disfiguring condition, neurofibromatosis 1.
The seventh annual 2018 Celebrating Distinction event honored faculty named to endowed professorships, chairs.
Following legendary physicist Stephen Hawking’s passing after battling ALS for more than 50 years, Dr. James Wymer discusses this unforgiving disease.